Bladder cancer treatments are hampered by high recurrence, requiring multiple therapeutic interventions which are highly invasive and cause side effects, underscoring the need for innovative treatments. In the pursuit of advancing bladder cancer treatment, immuno-oncology shows promise. This blog delves into the importance of identifying antigens in the development of targeted cancer therapies.  

Understanding GOF mutations is crucial for developing targeted therapies which inhibit the activity of aberrant proteins. Here, we explored FLT3 and NOTCH1 as GOF mutations associated with leukemia disease progression.

miRNA therapeutics face numerous challenges including targeted delivery, specificity, stability, immune response, and toxicity. Overcoming these challenges is paramount for success.

Head and neck cancers account for nearly 4% of all cancers in the US. The most common type is oral cancer, estimated to cause over 170,000 global deaths in 2020 alone. These statistics highlight the urgent need for more research and better treatments.

Gastrointestinal (GI) stromal tumors are a rare form of soft tissue sarcoma of the digestive system, primarily affecting the stomach and small intestine. In the US, approximately 6000 new cases of GI stromal tumors are diagnosed each year. Despite their rarity, these tumors are the most prevalent mesenchymal tumors of the GI tract.

Dive into groundbreaking research on Renal Cell Cancer, the most common kidney cancer in adults. Our blog explores innovative strategies for target identification, prioritization, and how these contribute to preventing and tackling this disease.